Pulse Biosciences (NASDAQ:PLSE) Stock Price Up 5.6% - Here's Why

Pulse Biosciences, Inc (NASDAQ:PLSE - Get Free Report) shot up 5.6% during trading on Monday . The company traded as high as $16.07 and last traded at $16.16. 79,563 shares traded hands during mid-day trading, a decline of 57% from the average session volume of 184,612 shares. The stock had previously closed at $15.30.

Wall Street Analyst Weigh In

A number of brokerages recently commented on PLSE. Oppenheimer began coverage on Pulse Biosciences in a research report on Monday. They issued an "outperform" rating and a $22.00 price target on the stock. Wall Street Zen raised Pulse Biosciences to a "sell" rating in a research note on Monday, March 31st.

Pulse Biosciences Stock Performance

The stock has a 50 day moving average price of $16.41 and a 200 day moving average price of $17.50.

Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.25) EPS for the quarter.

Insider Transactions at Pulse Biosciences

In other Pulse Biosciences news, CTO Darrin Uecker sold 15,000 shares of the business's stock in a transaction that occurred on Thursday, June 12th. The stock was sold at an average price of $16.40, for a total value of $246,000.00. Following the transaction, the chief technology officer directly owned 137,872 shares of the company's stock, valued at approximately $2,261,100.80. The trade was a 9.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 71.50% of the company's stock.

Hedge Funds Weigh In On Pulse Biosciences

Institutional investors have recently added to or reduced their stakes in the business. Farther Finance Advisors LLC lifted its stake in Pulse Biosciences by 24.6% in the first quarter. Farther Finance Advisors LLC now owns 8,998 shares of the company's stock valued at $143,000 after buying an additional 1,778 shares during the period. Vanguard Group Inc. lifted its stake in Pulse Biosciences by 15.1% in the fourth quarter. Vanguard Group Inc. now owns 1,146,339 shares of the company's stock valued at $19,958,000 after buying an additional 150,506 shares during the period. Deutsche Bank AG increased its holdings in shares of Pulse Biosciences by 65.1% during the fourth quarter. Deutsche Bank AG now owns 16,795 shares of the company's stock valued at $292,000 after acquiring an additional 6,625 shares in the last quarter. Barclays PLC increased its holdings in shares of Pulse Biosciences by 8.5% during the fourth quarter. Barclays PLC now owns 32,881 shares of the company's stock valued at $573,000 after acquiring an additional 2,575 shares in the last quarter. Finally, Rhumbline Advisers increased its holdings in shares of Pulse Biosciences by 6.3% during the first quarter. Rhumbline Advisers now owns 27,375 shares of the company's stock valued at $440,000 after acquiring an additional 1,614 shares in the last quarter. 76.95% of the stock is owned by institutional investors and hedge funds.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.